Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2006.12.058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Extranasal Neurostimulation for Patients With Neuropathic Corneal Pain: A Pilot Study.
Cornea
October 2024
Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; and.
Purpose: Neuropathic corneal pain (NCP) has been recognized as a distinct disease, yet treatment options remain limited. The aim of this pilot study was to explore the effectiveness of extranasal neurostimulation (EXNS) as a potential pain relief strategy for individuals with the peripheral component of NCP.
Methods: A retrospective study was performed to identify patients who were diagnosed with refractory peripheral or mixed NCP and subsequently underwent a single session of EXNS.
Chimeric Free Flaps Based on End-to-Side Anastomosis for Complex Lower Extremity Reconstruction.
Ann Plast Surg
December 2024
From the Department of Hand and Foot Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Background: Complex lower extremity defects are difficult to cover and often require multiple free tissue transfers. Chimeric anterolateral thigh free flaps (ALTF) and peroneal artery perforator free flaps (PAPF) have been designed specifically as an alternative for reconstruction with arterial end-to-side (ETS) anastomosis. We aimed to assess our institutional experience with this technique and to define its role in complex lower extremity reconstruction.
View Article and Find Full Text PDFBCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement.
Blood Adv
December 2024
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States.
We investigated BCMA-directed CART in patients with relapsed or refractory multiple myeloma (RRMM) and CNS involvement. Ten patients who received either ide-cel (n=6) or cilta-cel (n=4) were included in this analysis. Patients had brain/cranial nerve and/or spinal cord involvement/leptomeningeal disease evident on either MRI (100%) and/or CSF (40%).
View Article and Find Full Text PDFIsatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan.
Int J Hematol
December 2024
Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Kawasaki 1, Mizuno-cho, Mizuno-ku, Nagoya, Aichi, 467-8601, Japan.
This post-marketing surveillance (PMS) assessed the safety and effectiveness of isatuximab plus pomalidomide and dexamethasone (Isa-Pd) for relapsed or refractory multiple myeloma (RRMM) in frail individuals during real-world use in Japan. Data from all individuals with RRMM treated with Isa-Pd in Japan between October 2020 and October 2021 were collected, with follow-up continued up to 12 months after starting Isa-Pd or until discontinuation. In the overall PMS population, 40 participants were classified as frail (33.
View Article and Find Full Text PDFDorsal Root Ganglion Stimulation for Chronic Pelvic Pain Secondary to Endometriosis.
Neuromodulation
December 2024
Functional and Pain Clinic, Sao Paulo, SP, Brazil; Pediatric Neurosurgery, Washington University in St. Louis, St Louis, MO, USA. Electronic address:
Introduction: Chronic pelvic pain (CPP) is a multifaceted condition that poses significant challenges in clinical management owing to its complex and varied pathophysiology, including neuropathic, somatic, visceral, and musculoskeletal components. Endometriosis is frequently associated with CPP, necessitating a comprehensive, multimodal treatment strategy. This approach typically includes physical and behavioral therapy, pharmacologic interventions, surgical management of endometriosis, and various pain-modulating procedures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!